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Hyperhomocysteinemia is an independent risk factor
for the development of atherosclerosis. An increasing
body of evidence has implicated oxidative stress as
being contributory to homocysteine’s deleterious ef-
fects on the vasculature. Elevated levels of homocys-
teine may lead to increased generation of superoxide by
a biochemical mechanism involving nitric oxide syn-
thase, and, to a lesser extent, by an increase in the
chemical oxidation of homocysteine and other amino-
thiols in the circulation. The resultant increase in
superoxide levels is further amplified by homocysteine-
dependent alterations in the function of cellular antiox-
idant enzymes such as cellular glutathione peroxidase
or extracellular superoxide dismutase. One direct clini-
cal consequence of elevated vascular superoxide levels
is the inactivation of the vasorelaxant messenger nitric
oxide, leading to endothelial dysfunction. Scavenging
of superoxide anion by either superoxide dismutase or
4,5-dihydroxybenzene 1,3-disulfonate (Tiron) reverses
endothelial dysfunction in hyperhomocysteinemic ani-
mal models and in isolated aortic rings incubated with
homocysteine. Similarly, homocysteine-induced en-
dothelial dysfunction is also reversed by increasing the
concentration of the endogenous antioxidant glu-
tathione or overexpressing cellular glutathione peroxi-
dase in animal models of mild hyperhomocysteinemia.
Taken together, these findings strongly suggest that
the adverse vascular effects of homocysteine are at
least partly mediated by oxidative inactivation of nitric
oxide. Clin Chem Lab Med 2003; 41(11):1455–1461
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Introduction
Elevated plasma levels of homocysteine (hyperhomo-
cysteinemia) have been established as a risk factor for
atherothrombotic vascular disease during the last two
decades. The pathobiological mechanisms by which
homocysteine promotes atherothrombosis are not
completely understood as yet. One well-supported but
not universally accepted hypothesis suggests that hy-
perhomocysteinemia leads to increased oxidant stress
in the vasculature. This effect may be central to its pro-
motion of vascular pathology, partly by decreasing the
bioavailability of the endothelial antiatherogenic sig-
nalling molecule nitric oxide. The resulting endothelial
dysfunction is contributory to decreased vasodilator ca-
pacity, activation of circulating leukocytes and platelets,
activation of prothrombotic and inhibition of fibrinolytic
mechanisms, and stimulation of vascular smooth mus-
cle cell proliferation. All these effects participate in the
initiation and progression of atherosclerotic lesions and
thrombus formation (1). The purpose of this article is to
review recent advances in understanding the mecha-
nisms by which elevated levels of homocysteine induce
vascular oxidant stress, and the impact of such stress on
endothelial function in the clinical setting.
Hyperhomocysteinemia Is Associated with Increased
Superoxide Output
Experiments in hyperhomocysteinemic animals and
incubation of cultured endothelial cells with homocys-
teine indicate that elevated levels of homocysteine lead
to increased formation of reactive oxygen species. Aor-
tic tissue from mildly hyperhomocysteinemic heterozy-
gous cystathionine β-synthase-deficient (CBS–/+) mice
produces more superoxide anion compared to wild-
type mice (2), as measured by the lucigenin chemilu-
minescence assay or the cytochrome c assay. The
same effect could be demonstrated in cultured en-
dothelial cells incubated with homocysteine (3). This
enhanced superoxide formation seems to be a critical
determinant of homocysteine-induced endothelial dys-
function as scavenging of superoxide anion by either
superoxide dismutase or 4,5-dihydroxybenzene 1,3
disulfonate (Tiron) has been shown to reverse en-
dothelial dysfunction in hyperhomocysteinemic ani-
mal models (2, 4) and in isolated aortic rings incubated
with homocysteine (3). 
Superoxide anion reacts with nitric oxide in a diffu-
sion-limited reaction to form peroxynitrite (5), which
does not induce vasorelaxation (6), and is itself highly
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reactive. The potential physiological relevance of this
reaction is demonstrated by immunohistochemical and
immunoblot data showing an increase in protein tyro-
sine nitration, a marker of peroxynitrite-dependent pro-
tein oxidation, in vascular tissues from mildly hyperho-
mocysteinemic mice (2), and in lysates from aortic rings
cultured in homocysteine-containing media (7).
The role of hydrogen peroxide, which is produced
from superoxide via superoxide dismutase, in homo-
cysteine-induced endothelial toxicity in vitro is some-
what more nebulous. Early studies demonstrated that
catalase inhibits the homocysteine-induced lysis of en-
dothelial cells in the presence of transition metals or
ceruloplasmin (8, 9), but this lytic effect of homocys-
teine was only observed at concentrations far exceed-
ing those observed in the most severe cases of hyper-
homocysteinemia. More recently, we (Figure 1) and
others (10–12) have observed a homocysteine dose-
dependent increase in the fluorescence of an hydrogen
peroxide-sensitive fluorescent probe, 2’,7’-dichloroflu-
oresceine (DCF), in cultured endothelial cells, but the
interpretation of these results is tempered by the ob-
servation that DCF also fluoresces when it reacts with
peroxynitrite and reactive oxygen species other than
hydrogen peroxide. 
Mechanisms of Increased Vascular Oxidant Stress in
Hyperhomocysteinemia
Elevation of the oxidation rate of homocysteine in
hyperhomocysteinemia
Homocysteine is an intermediate in the methionine cy-
cle, the function of which is to generate one-carbon
methyl groups in the form of S-adenosylmethionine for
transmethylation reactions (13). The essential amino
acid methionine is the precursor of homocysteine. In
mammals, homocysteine can be diverted from the me-
thionine cycle into the transsulfuration pathway to gen-
erate the non-essential amino acid cysteine, or it can be
remethylated to methionine. Chemically, methionine
contains a sulfide sulfur (R-S-R’), whereas homocys-
teine and cysteine are sulfhydryl compounds (R-SH).
Compounds containing a free sulfhydryl group are
known as “thiols.” Other biologically relevant low-mol-
ecular-weight thiols are glutathione, coenzyme A, and
dihydrolipoic acid. Under aerobic conditions (i.e., in the
presence of molecular oxygen as an electron acceptor)
and at physiological pH, thiols such as homocysteine,
oxidize to form disulfides, according to the general re-
action 2 RSH + O2 ⇔ RSSR + H2O2. In plasma, this reac-
tion can be catalyzed by transition metals such as cop-
per and cobalt (the former present in the circulation
associated with albumin and ceruloplasmin, the latter
with cobalamin). Homocysteine has classically been
thought to autooxidize readily via this mechanism to
form homocystine, oxidize other thiols such as cys-
teine and glutathione to form mixed disulfides, or oxi-
dize free cysteine residues on proteins and peptides to
form mixed disulfides (Figure 2). This notion is sup-
ported by the observation that 1% or less of total ho-
mocysteine species consists of free homocysteine in
the plasma of healthy humans under physiological
conditions, whereas 5–15% consist of homocystine,
another 5–15% are mixed disulfides (cysteine-homo-
cysteine or glutathione-homocysteine), and more than
70% are protein-bound (14). Moreover, a decreased ra-
tio of reduced to total aminothiols in plasma has been
demonstrated in experimental hyperhomocysteinemia
after a methionine challenge (14–16) and in hyperho-
mocysteinemic patients (17–20). More recent evi-
Figure 1 Homocysteine dose-dependently increases the flu-
orescence of the reactive oxygen species-sensitive dye DCF in
cultured endothelial cells. EA-Hy 926 cells were loaded with
dichloroflurosceine-diacetate and incubated with different
concentrations of homocysteine and cysteine, respectively,
for 6 hours. Thrombin was used as a positive control. Intracel-
lular DCF-fluorescence was visualized using confocal laser mi-
croscopy and quantified by image analysis. The left panel
shows the mean ± SEM fluorescence intensity of four experi-
ments, and the right panel shows representative fluores-
cence-microscopy images. 
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dence, however, suggests that oxidized forms of ho-
mocysteine in plasma arise primarily via disulfide ex-
change, with only a small fraction resulting from direct
homocysteine oxidation (21). Hence, the contribution
of direct homocysteine oxidation to homocysteine-in-
duced vascular oxidative stress may not be as impor-
tant as enzymatic mechanisms. 
Involvement of nitric oxide synthase in the generation
of reactive oxygen species
Recent in vitro experiments (SH, NW, JL, JK, unpub-
lished observations) suggest that homocysteine-in-
duced oxidant stress is stereospecific for the naturally
occuring L-isoform, indicating a biochemical rather
than chemical basis for the effect. In these experi-
ments, increased lipid peroxidation was observed in
endothelial cells incubated with L-homocysteine, but
not with D-homocysteine, as measured by total iso-
prostane F2α-III and thiobarbituric acid reactive sub-
stances (TBARs) levels in the supernatant of endothe-
lial cell cultures. Stereospecificity was also observed
for DCF fluorescence in situ, indicating a parallel effect
on overall reactive oxygen species content. Enhanced
lipid peroxidation and DCF-fluorescence was not ob-
served with either cysteine or glutathione, and was not
due to extracellular thiol oxidation, as it could be fully
replicated with the oxidized disulfide form of homocys-
teine, L-homocystine. 
Mechanistically, this pro-oxidant effect seems to be
dependent upon both endothelial nitric oxide synthase
and superoxide anion. Pharmacological inhibition of
endothelial nitric oxide synthase with L-nitroarginine
methyl ester (L-NAME) completely blocked the homo-
cysteine-dependent stimulation of reactive oxygen
species formation as measured by DCF-fluorescence.
Furthermore, L-NAME completely abrogated both the
homocysteine-dependent increases in isoprostane
F2α-III formation and DCF fluorescence. Similarly, trans-
fection of endothelial cells with superoxide dismutase
cDNA blocked the effect of homocysteine on endothe-
lial cell lipid peroxidation, whereas addition of extra-
cellular superoxide dismutase had no effect. Impor-
tantly, neither the addition of extracellular catalase nor
loading cells with catalase had any effect on lipid per-
oxidation, indicating that hydrogen peroxide is not in-
volved in this process. 
The most straightforward explanation for these re-
sults would be that homocysteine induces increased
Figure 2 Chemistry of homocysteine and different homo-
cysteine oxidation products.
Figure 3 Hypothetical mechanism of nitric oxide synthase-
dependent generation of reactive oxygen species in hyperho-
mocysteinemia. L-homocysteine and L-homocystine, but not
the respective D-isoforms, increase membrane lipid peroxida-
tion and DCF-fluorescence in cultured endothelial cells. This
effect is dependent on endothelial nitric oxide synthase
(eNOS) and superoxide anion (O2–), as L-NAME and transfec-
tion of endothelial cells with superoxide dismutase cDNA, re-
spectively, block homocysteine’s effects. Increased O2– may
result from “uncoupling” of eNOS and/or from other enzy-
matic sources. Some of the excess O2– reacts with nitric oxide
(NO) to form peroxynitrite (ONOO–). This reaction leads to bio-
logical inactivation of NO. Furthermore, ONOO– initiates lipid
peroxidation and increases DCF-fluorescence.
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formation of peroxynitrite. Unlike superoxide, peroxy-
nitrite is both able to initiate lipid peroxidation (22) and
to react with DCF (23). Peroxynitrite has a short half-
life, which makes its detection difficult in biological
systems (24), but may react with cellular tyrosine
residues to form nitrosated endproducts. As men-
tioned earlier, immunostaining for one such endprod-
uct, 3-nitrotyrosine, was positive in aortic tissue from
mildly hyperhomocysteinemic CBS(–/+) mice compared
with wild-type mice (2), as was an immunoblot analysis
for 3-nitrotyrosine of protein lysates from aortic rings
cultured in homocysteine-containing media (7). 
Although the precise mechanism by which homo-
cysteine may induce increased peroxynitrite formation
remains to be elucidated, two potential mechanisms
include endothelial nitric oxide synthase “uncoupling”
(5, 25), in which endothelial nitric oxide synthase is the
source of superoxide (and peroxynitrite); and in-
creased superoxide production from other enzymatic
sources, in which some of the excess superoxide reacts
with nitric oxide to form peroxynitrite (Figure 3). 
Inhibition of cellular antioxidant enzymes by
homocysteine
The cellular defense system against reactive oxygen
species includes several antioxidant enzymes (Fig-
ure 4) and non-enzymatic antioxidants, such as α-toco-
pherol, ascorbic acid, β-carotene, and glutathione. Ho-
mocysteine has been shown in particular to disrupt the
normal function of two important cellular antioxidant
enzymes, the cellular isoform of glutathione peroxi-
dase (GPx-1) and superoxide dismutase.
Homocysteine, but not other low-molecular-weight
thiols, decreases both the expression and specific activ-
ity of GPx-1 as shown in vitro and in vivo (26–31). This
key enzyme for the cellular defense against oxidant
stress uses glutathione to reduce hydrogen peroxide
and lipid peroxides to their respective alcohols (32), and
may also act as a peroxynitrite reductase (33). Transi-
tion metal ions such as iron and copper catalyze the
breakdown of hydrogen peroxide to form hydroxyl rad-
ical (•OH), which is highly reactive and causes lipid per-
oxidation, among its numerous effects; and hydroxide
anion (OH–), which promotes alkaline tissue damage.
This process is offset in part by catalase and GPx-1-de-
pendent reduction of H2O2 to H2O. Elevated levels of
lipid peroxides are accompanied by an increase in per-
oxyl radicals, which can inactivate nitric oxide through
the formation of lipid peroxynitrites (34, 35). Thus a de-
ficiency of GPx-1 may lead to a decrease in bioavailable
nitric oxide via at least two mechanisms, an increase in
reactive oxygen species and an increase in lipid hy-
droperoxides. In support of this hypothesis we have
shown previously that mice deficient in GPx-1 have en-
dothelial dysfunction owing to decreased bioavailable
endothelium-derived nitric oxide; increased oxidative
stress and increased lipid hydroperoxide generation as
measured by increased tissue isoprostane F2α-III and
hepatic phospholipid hydroperoxide levels; and in-
creased nitrosative stress, as indicated by increased im-
munostaining for 3-nitrotyrosine in aortic tissue of
GPx-1 knockout mice compared to wild-type mice (36). 
Extracellular superoxide dismutase is a secreted gly-
coprotein with an affinity for heparin-like glycosamino-
glycans. It is present in the circulation in equilibrium
between the glycosaminoglycans on the endothelial
surface and the plasma phase, and acts as the principal
enzymatic scavenger of superoxide in the extracellular
space (37, 38). The plasma levels of extracellular super-
oxide dismutase correlate positively with plasma ho-
mocysteine levels in homocystinuric patients (39) and
in patients with mild hyperhomocysteinemia (40). This
effect is caused by decreased binding of extracellular
superoxide dismutase to endothelial cell surfaces by
alterations in the endothelial heparan sulfate proteo-
glycan by homocysteine (41). This effect may result in
a loss of the ability to protect the endothelial surface
from oxidative stress, although this hypothesis has not
yet been definitively proven.
In summary, experimental data suggest that ele-
vated levels of homocysteine lead to increased vascu-
lar generation of reactive oxygen species, primarily by
a mechanism involving nitric oxide synthase, and sec-
ondarily due to increased homocysteine oxidation.
These effects are further amplified by alterations in the
function of important cellular antioxidant enzymes.
The resultant vascular oxidant stress may lead to vas-
cular dysfunction.
Impact of Increased Vascular Oxidant Stress on
Homocysteine-Induced Endothelial Dysfunction
Endothelial dysfunction, which can be defined in part
as an impairment of endothelium-dependent vasoreac-
tivity and regulation of blood flow in the presence of
normal endothelium-independent vasodilation, ap-
pears to be a key event in homocysteine-induced vas-
cular pathobiology (1). Endothelial dysfunction has
been demonstrated in several different animal models
of mild hyperhomocysteinemia, including hyperhomo-
cysteinemia induced by vitamin-deficient and methion-
ine-enriched diets in cynomolgus monkeys (42) or rats
(43, 44), by heterozygous disruption of the cystathion-
ine β-synthase gene in mice (CBS(–/+) mice) (2, 30, 31), or
by the combination of genetic and dietary manipula-
tion (45). Endothelial dysfunction has also been
demonstrated in healthy humans with either acutely el-
evated plasma homocysteine levels following an oral
methionine challenge (46–56) or with chronic, mild hy-
perhomocysteinemia (57–59). 
In these studies, homocysteine impaired endothe-Figure 4 Enzymatic inactivation of reactive oxygen species.
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lium-dependent vasodilator function induced by shear
stress, acetylcholine, or bradykinin, but did not affect
endothelium-independent vasodilation induced by
sodium nitroprusside or nitroglycerin. These findings
indicate that the effects of homocysteine are due, at
least in part, to a decrease in endogenous bioavailable
nitric oxide. This conclusion is supported by the obser-
vation that the accumulation of cyclic guanosine
monophosphate, the second messenger of nitric ox-
ide-mediated vasodilation, was decreased in aortas
from mildly hyperhomocysteinemic CBS(–/+) mice com-
pared to their wild-type littermates (2), and that the
plasma levels of the nitric oxide-derived endproducts
nitrite and nitrate were significantly lower in hyperho-
mocysteinemic subjects than in healthy controls (59).
In accordance with these in vivo findings, homocys-
teine, but not cysteine, has been shown to decrease the
production and/or bioactivity of nitric oxide and of S-ni-
trosothiols by cultured endothelial cells (11, 26, 30). 
The link between vascular oxidant stress and the de-
velopment of homocysteine-mediated vascular patho-
biology has been established in in vivo studies in which
homocysteine-induced endothelial dysfunction was re-
versed by increasing cellular antioxidant capacity.
Treatment of hyperhomocysteinemic CBS(–/+) mice with
the intracellular cysteine donor L-2-oxo-4-thiazolidine
carboxylate, an agent that increases intracellular levels
of reduced glutathione and total thiols and thereby
shifts the cellular redox state to a more reduced envi-
ronment, restores endothelial function (31). Restora-
tion of normal endothelial function in hyperhomocys-
teinemic CBS(–/+) mice could also be achieved by
overexpression of cellular glutathione peroxidase (30).
This effect might be due to decreased oxidative inacti-
vation of nitric oxide, as overexpression of cellular glu-
tathione peroxidase in cultured endothelial cells has
been shown to attenuate the homocysteine-induced
decrease in nitric oxide release from these cells (30).
Further support for the link between homocysteine-de-
pendent endothelial dysfunction and oxidative stress
has been established in clinical studies demonstrating
that treatment with antioxidant vitamins prevents en-
dothelial and platelet dysfunction associated with hy-
perhomocysteinemia induced by oral methionine chal-
lenge (48, 50, 56, 60). Taken together, these findings
suggest that the adverse vascular effects of homocys-
teine are at least partly mediated by oxidative inactiva-
tion of nitric oxide. 
Potential Clinical Consequences
Several clinical studies, including 12 randomized and
placebo-controlled intervention trials, have shown that
supplementation with folic acid, vitamin B6, and vita-
min B12 lowers plasma homocysteine levels in most
patients (61). The reduction in plasma homocysteine
levels leads to normalization of endothelial function
(62–65). Whether or not this translates into a reduction
in cardiovascular morbidity and mortality is currently
under investigation in several intervention studies.
Plasma homocysteine levels cannot, however, be nor-
malized by vitamin supplementation in all cases. For
example, hyperhomocysteinemia persists even with
folic acid treatment (1–5 mg/day) in many patients with
chronic renal failure (66). Alternative therapeutic op-
tions directed at reducing the cardiovascular risk asso-
ciated with hyperhomocysteinemia are warranted
in these subgroups of patients. Antioxidant therapy
seems to be one such strategy. In this context it is
worth mentioning that, although the results of trials of
antioxidants for reducing cardiovascular morbidity and
mortality in the general population were disappointing
and did not show a benefit (67), there are two clinical
trials in patients with chronic renal failure that showed
a significant benefit of α-tocopherol or the thiol antiox-
idant N-acetylcysteine on cardiovascular morbidity
and mortality (68, 69). Whether or not this relates to an
effect of antioxidants on improving homocysteine-in-
duced endothelial dysfunction in patients with chronic
renal failure remains to be determined. Nevertheless
the experimental data reviewed here and the results of
these two clinical trials encourage further evaluation of
the effect of antioxidant strategies in selected groups
of patients at risk of cardiovascular disease, as in pa-
tients with hyperhomocysteinemia who do not re-
spond to folic acid supplementation.
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